- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Amlitelimab shows promising results for Atopic Dermatitis
Sanofi unveiled promising outcomes from its Phase 2b trial, STREAM-AD, during the European Academy of Dermatology and Venereology (EADV) 2023 Congress. The study assessed amlitelimab, a novel treatment for moderate-to-severe atopic dermatitis in adults with uncontrolled symptoms. The results were highly encouraging, showcasing the drug's potential to significantly enhance the lives of individuals for whom topical treatments are ineffective or not recommended.
In the dose-ranging trial, patients treated with subcutaneous amlitelimab displayed substantial improvements compared to a placebo, with statistically significant reductions in the Eczema Area and Severity Index (EASI) score over 16 weeks. Notably, amlitelimab 250 mg with a 500 mg loading dose demonstrated the most significant response, with a 61.5% reduction in EASI from baseline at week 16 and a 64.4% reduction at week 24.
The Chair of the Department of Dermatology and Allergy at the University Hospital Schleswig-Holstein, expressed enthusiasm about these findings. He emphasized that these results bring hope to patients suffering from persistent itch and skin lesions despite available treatments. The study also demonstrated a consistently positive impact on various aspects of the disease and maintained a favorable safety profile.
Amlitelimab achieved numerous secondary endpoints, such as improvements in the Investigator Global Assessment response, a 75% reduction in EASI, and a reduction in pruritus (itching). Amlitelimab's 250 mg with a loading dose particularly stood out, with 45.5% of patients achieving clear or almost clear skin (IGA 0/1) at week 24 and 54.5% attaining a 75% reduction in EASI.
Additionally, amlitelimab effectively reduced biomarkers associated with atopic dermatitis, including Th2-related IL-13 and TARC, Th17/Th22-related IL-17A and IL-22, and blood eosinophil counts. This reduction was observed as early as week 4 in the 250 mg with a loading dose arm.
Houman Ashrafian, Global Head of Research & Development at Sanofi, highlighted the significance of these results and their potential to transform the treatment landscape for atopic dermatitis. Sanofi's plans to initiate a Phase 3 development program in the first half of 2024 underscores their dedication to addressing this chronic condition.
Amlitelimab demonstrated an acceptable safety profile throughout the trial, with no new safety concerns identified. It is a fully human non-depleting monoclonal antibody targeting OX40-Ligand, which has the potential to become a first-in-class treatment for various immune-mediated and inflammatory disorders, including atopic dermatitis and asthma. It's important to note that amlitelimab is still under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory authority.
Source:
Press Release: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis. (n.d.). Sanofi.com. Retrieved October 15, 2023
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751